Welcome to our dedicated page for Kamada SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kamada Ltd (KMDA) SEC filings page on Stock Titan provides access to the company’s public reports as a foreign private issuer. Kamada files current reports on Form 6-K under the Securities Exchange Act of 1934, which include press releases, financial statements, presentations and other shareholder communications.
For Kamada, these filings are a primary source of information on its specialty plasma-derived therapies business, including proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Recent 6-Ks have attached quarterly and nine-month consolidated financial statements, discussions of revenues and adjusted EBITDA, and details on the performance of the Proprietary Products and Distribution segments.
Filings also document clinical and operational milestones, such as the discontinuation of the InnovAATe Phase 3 trial of Inhaled AAT following an interim futility analysis, the initiation of the investigator-initiated SHIELD study for CYTOGAM in kidney transplantation, and regulatory approvals for Kamada’s plasma collection center in Houston, Texas. Additional 6-Ks provide notices of annual general meetings, investor conference participation, and extensions of supply tenders, for example with Canadian Blood Services.
On Stock Titan, Kamada’s filings are updated as they are released to EDGAR, and AI-powered tools summarize key points from each document to help users interpret complex disclosures. Investors can review attached financial statements, presentations, and exhibits listed in the 6-K exhibit indexes, and track how Kamada reports on its growth pillars, plasma collection expansion, and business development activities over time.
Kamada Ltd Vice President of Business Development and Strategic Programs, Boris Gorelik, reported routine compensation-related option adjustments held indirectly by a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received several employee stock option awards, each for 3,750 Ordinary Shares at an exercise price of $9.13 per share, and returned options with the same share amount but a $9.38 exercise price to the issuer. Footnotes state the exercise prices are presented in U.S. dollars based on an exchange rate as of April 6, 2026, and were adjusted under the plan in connection with a cash dividend distribution, with no other changes to the option terms. These options vest in four equal 25% annual installments from the grant date and expire on February 11, 2027.
Kamada Ltd VP Human Resources Reshef Liron reported a series of option compensation adjustments involving employee stock options held by a trustee under the company’s 2011 Share Award Plan. The transactions combine option grants and corresponding dispositions back to the issuer with no net change in share count.
The filing shows multiple option awards over ordinary shares in blocks of 10,000 and 15,000, with exercise prices stated in U.S. dollars between $5.04 and $7.25, and corresponding adjustments from prior prices between $5.29 and $7.50. All options vest in four equal annual installments from each grant date and carry expirations between 2029 and 2035, reflecting routine compensation and price adjustments following a cash dividend.
Kamada Ltd Chief Executive Officer Amir London reported a series of compensation-related option changes, not open-market trading. A trustee under Kamada’s 2011 Share Award Plan received several grants of employee stock options for 100,000 ordinary shares each at exercise prices such as $5.87 and $7.25, while matching 100,000-option awards at $6.12 and $7.50 were returned to the company.
According to the notes, the exercise prices were adjusted under the 2011 Share Award Plan after a cash dividend declared on March 11, 2026, with no other changes to the award terms. The options vest in four equal annual installments and are held by a trustee under the plan.
Kamada Ltd director Karnit Goldwasser reported a series of employee stock option updates held indirectly through a trustee under the company’s 2011 Share Award Plan. The filing shows paired grant awards (code A) and dispositions back to the issuer (code D) in matching share amounts, leaving her net option position unchanged from these transactions.
The options cover Ordinary Shares with exercise prices converted from NIS, ranging from $5.87 to $7.48 per share and expirations between September 25, 2026 and June 22, 2029. A footnote explains the exercise prices were adjusted under the plan after a cash dividend declared on March 11, 2026, with no other changes to the award terms.
Kamada Ltd VP, Marketing & Sales Hanni Neheman reported compensation-related option changes involving 15,000 options held via a trustee under the 2011 Share Award Plan. On April 7, 2026, she received several grants of employee stock options to buy 15,000 Ordinary Shares at exercise prices including $5.87 and $7.25 per share and returned matching older options with higher exercise prices of $6.12 and $7.50 to the company.
The filing notes that exercise prices, presented in U.S. dollars, were adjusted from NIS following a cash dividend declared on March 11, 2026, with no other changes to the award terms. These options vest in four equal annual installments, 25% on each anniversary of the grant date, and expire between 2028 and 2035.
Kamada Ltd. director Assaf Itshayek reported administrative option changes rather than open‑market trading. On April 7, 2026, he indirectly, through a trustee under the company’s 2011 Share Award Plan, recorded several grants of 4,000 Employee Stock Options each and matching dispositions of prior options, all over ordinary shares. The options carry exercise prices shown in U.S. dollars, converted from NIS based on the Bank of Israel rate as of April 6, 2026, and those prices were adjusted under the plan following a cash dividend declared on March 11, 2026. Each award covers options expiring on March 7, 2030 and vesting in four equal annual installments, with 25% vesting on each anniversary of the grant date.
Kamada Ltd director Leon Recanati reported a series of administrative transactions in employee stock options held indirectly through a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received multiple option grants (code A) and simultaneously returned matching options to the issuer (code D) with slightly different exercise prices.
Footnotes explain that exercise prices in U.S. dollars are convenience translations from NIS and were adjusted under the plan following a cash dividend declared on March 11, 2026, with no other changes to the awards’ terms. The options vest in four equal annual installments, and there were no open‑market purchases or sales of ordinary shares disclosed.
Kamada Ltd director Dekel Benjamin reported routine employee stock option adjustments held indirectly through a trustee under the company’s 2011 Share Award Plan. On the same date, he both received and returned options covering 4,000 ordinary shares in offsetting grant and disposition entries.
The options carry exercise prices shown in U.S. dollars as a convenience from NIS and were adjusted under the plan following a cash dividend declared on March 11, 2026. The award vests in four equal annual installments from the grant date and expires on March 7, 2030, leaving 4,000 options reported as outstanding after these transactions.
KAMADA LTD VP and General Counsel Nir Livneh reported a series of employee stock option grants and related option adjustments held via a trustee under the company’s 2011 Share Award Plan. The transactions show awards of options to buy Ordinary Shares at exercise prices stated in U.S. dollars for convenience, paired with corresponding dispositions of options back to the issuer reflecting adjusted exercise prices following a cash dividend distribution. The options vest in four equal annual installments from their grant dates and have expiration dates ranging from late 2029 to late 2035, indicating long-term, compensation-related equity exposure rather than open-market share trading.
Kamada Ltd Chief Financial Officer Chaime Orlev reported a series of administrative option adjustments under the company’s 2011 Share Award Plan. All entries relate to employee stock options held indirectly by a trustee, not to open-market share purchases or sales.
The filing shows nine grants and nine matching dispositions of options on ordinary shares, with exercise prices such as $5.87, $5.90, $6.12, $6.15, $7.25 and $7.50 per share presented in U.S. dollars. Footnotes explain that exercise prices were adjusted under the plan following a cash dividend declared on March 11, 2026, and that options vest in four equal annual installments.